Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Capecitabine in HR+ Metastatic Breast Cancer
NCT05064085Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemiplimab in breast cancer (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Oct 2021; status: completed.
02
Drugs
cemiplimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05064085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064085.